An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques
| Autor: | Aymeric de Montfort, Florence Boudet, Catherine C. Berry, Arnaud Donadieu, Vincent Pavot, Nicolas Jackson, Bachra Rokbi, Jon Heinrichs, Valerie Lecouturier |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
lcsh:Immunologic diseases. Allergy
0301 basic medicine Immunology Drug development lcsh:RC254-282 Viral infection Article Zika virus 03 medical and health sciences 0302 clinical medicine Medicine Pharmacology (medical) Seroconversion Pharmacology biology business.industry Immunogenicity lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens biology.organism_classification Virology 030104 developmental biology Infectious Diseases Inactivated vaccine lcsh:RC581-607 business 030217 neurology & neurosurgery |
| Zdroj: | NPJ Vaccines npj Vaccines, Vol 5, Iss 1, Pp 1-10 (2020) |
| ISSN: | 2059-0105 |
| Popis: | The recent spread of Zika virus (ZIKV) through the Americas and Caribbean and its devastating consequences for pregnant women and their babies have driven the search for a safe and efficacious ZIKV vaccine. Among the vaccine candidates, a first-generation ZIKV purified inactivated vaccine (ZPIV), adjuvanted with aluminum hydroxide, developed by the Walter Reed Army Institute of Research (WRAIR), has elicited high seroconversion rates in participants in three phase-I clinical trials. In collaboration with the WRAIR, Sanofi Pasteur (SP) optimized the production scale, culture and purification conditions, and increased the regulatory compliance, both of which are critical for clinical development and licensure of this vaccine. Using a clinical batch of the first-generation ZPIV as a benchmark, we report that different doses of the optimized vaccine (ZPIV-SP) elicited sustained neutralizing antibodies, specific T- and memory B-cells, and provided complete protection against a ZIKV challenge in cynomolgus macaques. These data provide evidence that the ZPIV-SP vaccine performs at least as well as the ZPIV vaccine, and provide support for continued development in the event of future ZIKV outbreaks. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|